LETTER TO THE EDITOR

Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis

Jamie O’Hara1,2†, Ceri Hirst3*†, Jose Francisco Cabre Marquez4† and Tom Burke2†

Abstract

Background: Untreated hemophilia A patients may experience recurrent bleeding events leading to debilitating joint damages. While RCT and pharmacokinetic data support the value of Kovaltry [an unmodified full-length recombinant factor VIII (FVIII) product], real world evidence in children is lacking. This report describes a descriptive and multivariate analysis of the effectiveness of Kovaltry in children with hemophilia A in the real-world setting, using data from medical chart abstraction and cross-sectional surveys of physicians, patients, and caregivers.

Results: Male patients aged < 18 years with moderate or severe hemophilia A, residing in five European countries and treated with FVIII were studied. The co-primary endpoints were the annualized bleeding rate (ABR) and the annual FVIII utilization rate. Twenty nine patients treated with Kovaltry were included, of whom 93% had severe disease and 75% were on continuous prophylactic treatment. The mean ABR was 2.66 ± 2.06, with rates decreasing with age. The children received on average 2.45 infusions per week, consistent across age groups (median 3; range 1–3). There were no reports of inhibitor development or adverse events in the study (AEs), and all patients were satisfied or very satisfied with the treatment. An exploratory multivariate analysis suggests no significant difference in ABR or units utilized between Kovaltry and some extended half life products in children with severe hemophilia A, though characteristics of these patient cohorts were markedly different.

Conclusion: This analysis demonstrates the effectiveness and safety of Kovaltry in a pan-European pediatric population with severe hemophilia A.

Keywords: Hemophilia A, Kovaltry, Real world evidence, Factor utilization, Clinical burden

Introduction

Hemophilia A is a rare X-linked genetic disorder characterized by deficiency of coagulation factor VIII (FVIII) [1–4]. Individuals with severe hemophilia have FVIII levels less than 1% of that expected in a healthy person [5, 6]. Such patients, if not optimally treated, encounter recurrent bleeding episodes causing cumulative damage and commonly arthropathy [7, 8].

In Western European countries, around 90% of children with severe hemophilia A now have access to specialist care teams and prophylactic treatment with replacement FVIII, which is proven to reduce bleeding events and resultant joint damage [9–12]. Two main types of replacement FVIII are now available; standard half-life products (SHL) with half-life of around 8–12 h [13], and more recently, so-called extended half life products (EHL) [14, 15]. Two EHL products were approved in Europe at the time of this study: Elocta (Sobi) in 2015 [14] and Adynovate (Takeda) in 2018 [15] only for people over the age of 12 years. There is little evidence on the
relative clinical effectiveness of SHL and EHL products in the real world setting and particularly in children.

Kovaltry is an unmodified full-length recombinant SHL FVIII product, yet pharmacokinetic analyses have shown an increased half-life for Kovaltry when compared with traditional FVIII products in adult hemophilia A patients, and consistency in terminal half-life for children across all age groups [16–19]. Currently there is an evidence gap in translation of the improved PK profile to clinical benefits in children: real-world utilization, safety, and effectiveness, particularly in comparison with EHL products.

The primary objective of this study was to describe the effectiveness of Kovaltry in children with hemophilia A in the real-world setting.

Methods
A nested cohort analysis was conducted utilizing data as captured in the Cost of Haemophilia in Europe: a Socio-economic Survey (CHESS) Pediatrics study [20, 23]. Clinical- and patient-reported data were obtained between December 2017 and April 2018 via medical chart abstraction, including 12 months of retrospective clinical data and cross-sectional surveys from physicians and patients/caregivers. Males aged less than 18 years who had moderate or severe hemophilia A; resided in France, Germany, Italy, Spain, or the United Kingdom (UK); and who were treated with FVIII were included in analyses. The co-primary endpoints were the annualized bleeding rate (ABR) as reported by the physicians in the survey and the annual Kovaltry utilization. Standard descriptive analyses were used to describe baseline characteristics and outcomes associated with the included patients [21].

In an exploratory analysis, we compared the characteristics of patients treated with Kovaltry and EHL products in this real world setting. The impact of covariates on outcome variables was assessed using a generalized linear model (GLM) procedure with stepwise model selection to control covariates and minimize the confounding effect. ABR was described and included as a covariate in the multivariate analysis of treatment utilization. Conversely, treatment utilization was included in the ABR model. Sensitivity analysis excluded patients having a treatment dose considered by the steering committee to be unfeasible: <2.5 IU/kg/week and >200 IU/kg/week. Statistical analyses were performed using SAS® software Version 9.4.

The sample size was driven by the full number of eligible patients available in the dataset, with no further restrictions. The rarity of haemophilia A often limits the sample size available for research, particularly in children, and although CHESS Pediatrics provides one of the largest datasets in this population, the statistical power is limited. As such, all analyses are considered descriptive and exploratory.

Results
In the primary descriptive analysis of Kovaltry, 29 children were included (Table 1). Nearly all patients had severe hemophilia (93.1% n = 27). Most were on continuous prophylaxis at the initiation of the study (74.9%; n = 22). Target joints at the study initiation were rare (11%).

The mean annual bleeding rate in patients treated with Kovaltry was 2.66 (SD ± 2.06). The data demonstrated a reduction in rates of bleeding according to age categories, from 4 ± 2.92 in the youngest children aged 0–5 years, 2.67 ± 1.84 in those aged 6–11 years, and in the sub group aged 12–17 years 1.89 ± 1.69. Around 20% of the patients who were receiving Kovaltry were free of bleeds; (n = 6). Within the 22 patients receiving Kovaltry prophylactically, the mean ABR was 2.18, and after excluding one patient with an unfeasible dosage was 1.90. On average, these patients were prescribed 2.45 infusions per week (median 3; range 1–3).

There were no reports of inhibitor development or any adverse events (AEs) with Kovaltry. Most patients (86.2%; n = 25) were considered by their physician to be adherent to their prescribed treatment regimen (missing <15% of infusions). All patients who responded to the linked patient survey were satisfied with the treatment, and 60% were very satisfied.

Exploratory analysis
In the exploratory analysis, 82 patients were included (22 Kovaltry and 60 EHL). Characteristics of patients prescribed Kovaltry and EHL differed considerably. Patients in the Kovaltry cohort were younger in age, had more severe disease, and started prophylactic treatment at a younger age. Patients in the EHL cohort were more likely to have had recurrent inhibitors, target joints, and damaged joints. The physician-reported adherence rate was similar between both groups (Table 1).

The mean ABR in the Kovaltry cohort was lower than with EHL (ABR 1.90 ± 1.58 vs 4.14 ± 7.88 respectively, P = 0.04). After statistical adjustment for differences in baseline patient characteristics (age, severity, utilization, presence of target or chronic joints), the difference was not statistically significant (ABR 2.18 ± 1.55 vs 4.06 ± 0.90 respectively P = 0.31). ABR remained lower in Kovaltry treated patients across all age groups (0–11 years 2.36 vs. 4.33 and 12–17 years 1.63 vs. 3.93 for Kovaltry and EHL, respectively) (Fig. 1), and a higher proportion of patients in the Kovaltry cohort had zero annual bleed rates when compared with EHL (27.3% vs. 10%).
The mean weekly infusion frequency was comparable between the Kovaltry and the EHL group (2.43 vs. 2.28) and was similar across all age groups.

The calculated median factor utilization was lower in the Kovaltry group than in the EHL group (weekly 80.1 IU/kg vs 89.9 IU/kg; P=0.43). When adjusting for differences in baseline characteristics in multivariate analyses, there was a numerical, but not statistically significant, difference between Kovaltry and EHL cohorts, (74.84 IU/kg vs. 88.83 IU/kg; P=0.23).
Discussion
While randomized clinical trials (RCTs) are recognized as the gold standard for evaluating the efficacy of new products, in a real-world setting both the characteristics of patients and the way in which products are used can differ from the trial setting [22, 23]. Therefore, this RWE in pediatric patients across Europe adds to the scientific knowledge of hemophilia A treatment.

This current analysis supports the strong profile of Kovaltry, with a low mean annual bleeding rate of 2.18, ranging from 2.67 to 1.89 from the youngest to the oldest patients, in line with clinical and pharmacokinetic expectations [17–20]. 100% patient satisfaction and an average of 2.45 infusions per week were reported. No adverse events or inhibitor development was reported, in line with previous research [12–14].

The exploratory analysis demonstrates that, at the time of the analysis, children prescribed EHL products had markedly different characteristics from those prescribed Kovaltry, being typically older and more likely to have had recurrent inhibitors, target joints, and damaged joints. The noted non-significant differences in ABR and utilization must be interpreted cautiously in light of the low sample size, due to the disease rarity, limited available EHLs at the time of the study, restriction of use to only patients aged above 12 years for Adynovi, and potential for residual confounding factors. Full clinical details of joint involvement, such as imaging, were also not available in the study dataset.

This study highlights the importance of observational data to better understand the utilization of new FVIII products in the real world, particularly how this may impact patient management and outcomes. It also indicates that further research may be warranted to understand the relative value of FVIII products in children.

Abbreviations
ABR: Annualized bleeding rate; AEs: Adverse events; AUC: Area under the plasma drug concentration–time curve; BMI: Body mass index; CHESS: Cost of Haemophilia in Europe: a Socioeconomic Survey; CI: Confidence intervals; EHL: Extended half-life; EMA: European Medicines Agency; FVIII: Factor VIII; GLM: Generalized linear model; n/N: Number; PK: Pharmacokinetic; RCTs: Randomized clinical trials; RWE: Real-world evidence; SD: Standard deviation; SE: Standard error; SHL: Standard half-life; UK: United Kingdom.

Acknowledgements
The authors gratefully acknowledge all contributors to the CHESS Pediatrics study, and Venkateswaraprasad Gali of Apcrels for medical writing support.

Author’s contributions
JO and TB designed the CHESS study, managed the data collection, assembled the database, and cleaned the data for analysis. CH designed and managed the analysis, and prepared the findings. JM provided medical support for the analysis and results interpretation. All authors prepared the manuscript and verify the contents. All authors read and approved the final manuscript.

Funding
This analysis was funded by Bayer Consumer Care.

Availability of data and materials
All the data was collected from the CHESS Pediatrics study and is available with the corresponding author upon reasonable request.

Ethics approval and consent to participate
The CHESS protocol was approved by the ethics committee of the University of Chester, UK.

Consent for publication
Not applicable.

Competing interests
J O’Hara and T Burke have received consulting fees from Bayer as well as several other pharmaceutical companies. J Cabre Marquez and C Hirst are current employees of Bayer.

Author details
1 Department of Health and Social Care, University of Chester, Chester, UK
2 HCD Economics, Daresbury, UK
3 Real World Evidence, Bayer, Basel, Switzerland
4 Global Medical Affairs, Bayer, Mexico City, Mexico.

Received: 11 September 2020 Accepted: 5 January 2021
Published online: 13 January 2021

References
1. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–97.
2. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The hemophilia surveillance system project investigators. Am J Hematol. 1998;59(4):288–94.
3. Data & Statistics on Hemophilia. Center for Disease Control and Prevention. Page Last reviewed: 21 June, 2019. https://www.cdc.gov/nchbddd/hemophilia/data.html. Accessed 19 Mar 2020.
4. National Hemophilia Foundation. Last updated: 21 Jun 2019. https://www.hemophilia.org/About-Us/Fast-Facts. Accessed 19 Mar 2020.
5. Mejía-Carvajal C, Cazpek EE, Valentino LA. Life expectancy in hemophilia outcome. J Thromb Haemost. 2006;4:507–9.
6. Darby SC, Kan SW, Spooner RJ, Giangrande PLF, Hill FGH, Hay CRM, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815–25.
7. World Federation of Hemophilia. Frequently asked questions about hemophilia. 2012. http://www.wfh.org/en/page.aspx?pid=637#life_expectancy. Cited 31 Jul 2015.
8. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost. 2010;8:1895–902.
9. World Hemophilia Federation. https://www1.wfh.org/publications/files/pdf-1472.pdf.
10. World Federation of Hemophilia: Report on the Annual Global Survey 2015. 2015. Accessed 19 Mar 2020.
11. Lindvall K, von Mackensen S, Elmståhl S, Khair K, Stain AM, Ljung R, et al. Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatr Blood Cancer. 2014;61:706–11.
12. DeKoven M, Karkare S, Kelley LA, Cooper DL, Pharm H, Powers J, et al. Understanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United States. Haemophilia. 2014;20:541–9.
13. Role of new prolonged half-life clotting factors in hemophilia. National Hemophilia Foundation. https://www.hemophilia.org/data.html. Accessed 19 Mar 2020.
14. ADYNOVI 250 IU/5 ml powder and solvent for solution for injection. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/adynoviepar-product-information_en.pdf. Accessed 19 Dec 2020.
15. ADYNOVI 250 IU/5 ml powder and solvent for solution for injection. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/adynovi-par-product-information_en.pdf. Accessed 19 Dec 2020.
for BAY 81–8973 compared with other full-length rFVIII products. Drug Des Devel Ther. 2019;13:941–8.

17. Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, investigators of the LEOPOLD Kids Trial, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia. 2016;22(3):354–60.

18. Saxena K, Lalezari S, Oldenburg J, Tseneklidou-Stoeter D, Beckmann H, Yoon M, et al. Efficacy and safety of BAY 81–8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2016;22(5):706–12.

19. Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas M, Enriquez M, LEOPOLD II Study Investigators. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360–9.

20. O’Hara J, Hughes D, Camp C, Burke T, Carroll L, Garcia Diego DA. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106.

21. O’Hara J, Khair K, McLaughlin P, O’Mahony B, Laffan M, Pasi J, et al. “Problem Joint”—a more patient relevant definition for joint morbidity in haemophilia. Poster Presented at the European Association for Hemophilia and Allied Disorders (EAHAD): 6–8 February, 2019, Czech Republic.

22. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551–5.

23. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375:2293–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.